文献速递泌尿生殖与妇科肿瘤放疗

短期雄激素剥夺治疗联合放疗对中危前列腺癌的获益

The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-02-06

该研究是对7项III期随机对照试验(6179例中危前列腺癌患者)的随机效应荟萃分析,评估放疗联合短期雄激素剥夺治疗(ST-ADT)的疗效。结果显示ST-ADT显著改善总生存(HR 0.88,95%CI 0.79-0.97,P=0.01)和生化控制(HR 0.50,95%CI 0.37-0.68,P<0.001),模拟患者数据证实10年绝对生存获益为5%。

要点

  • ST-ADT联合放疗显著改善中危前列腺癌患者的总生存(HR 0.88,95%CI 0.79-0.97,P=0.01)。
  • ST-ADT显著改善生化失败(HR 0.50,95%CI 0.37-0.68,P<0.001)和生化进展无进展生存(HR 0.54,95%CI 0.46-0.65,P<0.001)。
  • 模拟患者水平数据证实10年绝对生存获益为5%(HR 0.85,95%CI 0.76-0.96,log-rank P=0.021)。

核心结论

  • 该分析证实ST-ADT可改善未选择的中危前列腺癌患者的总生存和基于前列腺特异性抗原的结局,达到临床显著程度。

研究设计与样本

  • 系统综述纳入1980年1月至2024年10月发表或报告的III期随机对照试验,比较放疗联合或不联合ST-ADT在中危前列腺癌患者中的疗效。
  • 共纳入7项随机对照试验(NRG/RTOG 9408、DFCI 95-096、TROG 96.01、PCS III、EORTC 22991、NRG/RTOG 0815和GETUG-14),报告6179例患者的结局。
  • 采用研究水平的随机效应荟萃分析,主要终点为总生存,次要终点为至生化失败时间和生化进展无进展生存。
  • 采用荟萃回归探索与治疗效应相关的试验水平因素,并汇总模拟的个体患者水平总生存数据进行确认和估计相对及绝对生存获益。

主要发现

  • 汇总风险比:总生存HR 0.88(95%CI 0.79-0.97,P=0.01);生化失败HR 0.50(95%CI 0.37-0.68,P<0.001);生化失败+生化进展无进展生存HR 0.54(95%CI 0.46-0.65,P<0.001)。
  • ST-ADT持续时间、放疗剂量和Gleason评分试验人群构成均与ST-ADT对生化疾病控制的获益增加相关(均P<0.05),但与总生存无关(均P>0.05)。
  • 汇总模拟的个体患者水平数据证实存在生存获益(HR 0.85,95%CI 0.76-0.96,log-rank P=0.021),对应10年绝对生存获益为5%。

关键数值与推荐

  • ST-ADT联合放疗对比单纯放疗:总生存HR 0.88(95%CI 0.79-0.97,P=0.01)。
  • ST-ADT联合放疗对比单纯放疗:生化失败HR 0.50(95%CI 0.37-0.68,P<0.001)。
  • ST-ADT联合放疗对比单纯放疗:生化失败+生化进展无进展生存HR 0.54(95%CI 0.46-0.65,P<0.001)。
  • 模拟个体患者数据:总生存HR 0.85(95%CI 0.76-0.96,log-rank P=0.021),10年绝对生存获益5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A previous, individual patient-level meta-analysis of randomized controlled trials (RCTs) demonstrated the overall survival (OS) benefit of short-term androgen deprivation therapy (ST-ADT) when delivered with radiation therapy (RT) for the subset of patients with intermediate-risk prostate cancer (IR-PCa). However, because of inclusion criteria, several studies such as NRG/RTOG 0815, GETUG-14, and DFCI 95-096 were excluded. Thus, we conducted the present analysis, inclusive of all studies to define the current role of ST-ADT in IR-PCa. METHODS AND MATERIALS: A systematic review was conducted of phase 3 RCTs published or presented between January 1980 and October 2024 which profiled the comparative efficacy of radiation therapy ± ST-ADT in patients with IR-PCa. A study-level, random-effects meta-analysis was performed. The primary endpoint of this meta-analysis was OS, with secondary endpoints of time-to-biochemical failure (BF) ± biochemical-progress-free survival (bPFS). Meta-regression was used to explore trial-level factors associated with treatment effects. Synthetic individual patient-level OS data were pooled for confirmation and used to estimate the relative and absolute survival benefit. RESULTS: Seven RCTs (NRG/RTOG 9408, DFCI 95-096, TROG 96.01, PCS III, EORTC 22991, NRG/RTOG 0815, and GETUG-14) reporting outcomes of 6179 patients were identified. The pooled hazard ratios (HRs) for HROS, HRBF, and HRBF+bPFS were 0.88 (95% confidence interval [CI], 0.79-0.97; P = .01), 0.50 (95% CI, 0.37-0.68; P < .001), and 0.54 (95% CI, 0.46-0.65; P < .001), respectively. ST-ADT duration, RT dose, and Gleason score trial population composition were each associated with an increased benefit of ST-ADT for biochemical disease control (all P < .05) but not for OS (all P > .05). Pooling of simulated, patient-level data confirmed the presence of a survival benefit (HROS, 0.85 [95% CI, 0.76-0.96], log-rank P = .021), corresponding to an absolute survival benefit of 5% benefit at 10 years. CONCLUSIONS: The present analysis confirms current knowledge that ST-ADT improves both OS and prostate-specific antigen-based outcomes for unselected patients with IR-PCa to a clinically significant degree.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Patel KR, Spratt DE, Tran PT, et al. The Benefit of Short-Term Androgen Deprivation Therapy with Radiation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 39922318. doi:10.1016/j.ijrobp.2025.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。